Bactolife

Founded 2017
Employees 40+
Primary contact
Rønnegade 8
2100 Copenhagen
Denmark
Diseases & Conditions
Sections
Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting growth or killing the bacteria directly. The company is developing and will market ingredients for Mothers & Children, Elderly, Immunodeficient, Travelers & Deployed and Animal Health. The company has proof of concept (PoC) of its technology among others from testing its most advanced animal health product, Ablacto+ that stabilizes the gut of piglets and reduce the severity of post weaning diarrhea (PWD), in more than 6,000 piglets.
Founded 2017
Employees 40+
Primary contact
Rønnegade 8
2100 Copenhagen
Denmark
Diseases & Conditions
Sections

Funding 💰

Total $46.4M
Last round 🔗 €30M
Series A
August 8, 2023.
Select investors ATHOS, Bill & Melinda Gates Foundation, Novo Holdings, Selfinvest

Key people 🧑‍🤝‍🧑

Highlights

  • Solving the problem: Globally, there are more than 1.6 billion cases of diarrheal diseases annually which at best means stomach upsets. At worst, they can lead to life-threatening illnesses. Annual healthcare costs are increasing, and there are limited options to avoid disease manifestation in the first place. It is estimated that 760,000 children die annually from gut infections, and in those who survive, both infections later in life and growth stunts are observed. Today, most infections are treated with antibiotics that are either highly expensive or contribute to the spread of antibiotic resistant bacteria. Bactolife takes a unique approach to gut health for the greater good of humans and animals by developing Binding Proteins that can reduce the risk of developing gut health infections, thereby reducing the need for antibiotics, at an affordable price point.
  • Revolutionary new way for gut health: Instead of treating gut infections by merely killing harmful microbes, Bactolife builds on nature's design using a spectrum of Binding Proteins for an infinite number of uses. Its Binding Proteins bind specifically to virulence factors produced by harmful microbes, neutralizing any negative effect before they become an issue in the gut, without destroying the beneficial microbiome.
  • Protection at any age: From infant formula to dietary supplements, Binding Proteins can protect at any age and fit in various formulations. They are also very stable, can tolerate harsh environments, and still maintain their supporting function.

Video ▶️

Quotes 💬

Infectious diseases and increasing antimicrobial resistance are amongst the biggest threats to global health and development. We are committed to addressing this challenge and believe in Bactolife's targeted solutions.
Julian Zachmann, Investment Manager at ATHOS 🔗
The successful Series A is another validation of Bactolife's impressive achievements and opportunity for the future. Bactolife is a great example of the strong Danish biotech ecosystem, as its technology platform originates from a Danish University, and was then further enabled by pioneering Danish biotech companies and talents. This bodes well for the future of not only Bactolife, but the Danish biotech sector as a whole. Further, I am very pleased that the international investors share our enthusiasm for finding solutions to the global AMR crisis. Combatting antimicrobial resistance requires all hands on deck.
Aleks Engel, Partner at Novo Holdings 🔗
Last update: August 11, 2023